Iranmanesh Marzieh, Fatemi S Jamil A, Ebrahimpour Roza, Dahooee Balooch Faezeh
Chemistry Department, Shahid Bahonar University of Kerman, 22 Bahman Blvd, PO BOX 76961, Kerman, Iran.
Biometals. 2013 Jun;26(3):465-71. doi: 10.1007/s10534-013-9631-5. Epub 2013 May 14.
The present research is aimed to characterize the potential efficiency of two chelators after chromium(VI) administration for 60 days following two doses of 15 and 30 mg/kg chromium(VI) per body weight daily to male rats. However, the hypothesis that the two chelators might be more efficient as combined therapy than as single therapy in removing chromium(VI) from rat organs was considered. In this way, two known chelators deferasirox and deferiprone were chosen and given orally as a single or combined therapy for a period of 1 week. Chromium(VI) and iron concentrations in tissues were determined by flame atomic absorption spectroscopy. The combined chelation therapy results show that deferasirox and deferiprone are able to remove chromium(VI) ions from various tissues while iron concentration returned to normal levels and symptoms also decreased.
本研究旨在表征两种螯合剂在按每日每体重15和30毫克/千克六价铬给雄性大鼠连续给药60天后的潜在效果。然而，有人认为，与单一疗法相比，两种螯合剂联合治疗在从大鼠器官中去除六价铬方面可能更有效。通过这种方式，选择了两种已知的螯合剂地拉罗司和去铁酮，并以单一或联合疗法口服给药1周。通过火焰原子吸收光谱法测定组织中的六价铬和铁浓度。联合螯合疗法的结果表明，地拉罗司和去铁酮能够从各种组织中去除六价铬离子，同时铁浓度恢复到正常水平，症状也有所减轻。
